Clinical Trial Update: huCART19-IL18 in CD19+ Cancers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of huCART19-IL18 for CD19+ cancers is currently ACTIVE_NOT_RECRUITING, sponsored by the University of Pennsylvania, including chronic lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• huCART19-IL18 (CAR-T cell therapy expressing IL-18 targeting CD19)

Snippet

Sponsor: University of Pennsylvania | Conditions: Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING